bRo5: Macrocyclics, Degraders, & More Icon

Cambridge Healthtech Institute’s 2nd Annual

bRo5: Macrocyclics, Degraders & More

Designing Drug-Like Large Molecules beyond the Rule of Five

APRIL 12 - 13, 2023

 

A new frontier for discovery chemists is designing larger molecules such as macrocyclics, constrained peptides, or bifunctional degraders for targeted protein degradation (TPD) applications, that are better able to combat difficult intracellular targets than are small molecules. The difficulty is for such compounds to retain the favorable drug properties of small molecules: oral bioavailability, solubility, and cell permeability. In other words, going beyond Lipinski’s rule of five is becoming a more common challenge. At Cambridge Healthtech Institute’s 2nd Annual bRo5 conference, join fellow medicinal, computational, and synthetic chemists to discuss success stories and survey the field to discuss strategies for addressing these newer ‘large small molecule’ drug modalities.






For more details on the conference, please contact:

Anjani Shah, PhD

Senior Conference Director and Lead Content Director for Drug Discovery Chemistry

Cambridge Healthtech Institute

Phone: (+1) 781-247-6252

Email: ashah@healthtech.com

 

For sponsorship information, please contact:

Kristin Skahan

Senior Business Development Manager

Cambridge Healthtech Institute

Phone: (+1) 781-972-5431

Email: kskahan@healthtech.com